The impact of implementation of neuromuscular blockade monitoring standards in a surgical intensive care unit.
The purpose was to determine whether implementation of standards for peripheral nerve monitoring could decrease the incidence of neuromuscular dysfunction related to the administration of paralytic agents. Over a 2-year period, consecutive patients admitted to a surgical intensive care unit who received continuously-infused or >6 daily doses of neuromuscular blocking agents were subjected to train-of-four (TOF) monitoring of the adductor pollicis. Therapy was titrated to the maintenance of one to two twitches at all times. The incidence of prolonged (>12 h) paralysis after drug discontinuation was documented in these patients and compared to that in patients treated in the previous 12 months. The presence of electrolyte abnormalities, organ dysfunction, and concomitant medications was also recorded. Chi-square analysis with Yates correction was employed. Before implementation of routine TOF monitoring, there were five instances of paralytic-associated neuromuscular dysfunction (5/43). After implementation of the TOF protocol, no instances of paralytic-associated neuromuscular dysfunction occurred (0/90), despite the same incidence of risk factors (100%) (P < 0.05). A protocol for neuromuscular blockade monitoring is efficacious in preventing paralytic-associated neuromuscular dysfunction. This can be a cost-effective measure, minimizing the prolonged mechanical ventilation and intensive rehabilitation required secondary to unmonitored use of neuromuscular blocking agents.
Frankel
H
H
Department of Surgery, The Washington Hospital Center, D.C., USA.
Jeng
J
J
Tilly
E
E
St Andre
A
A
Champion
H
H
D000368:Aged; D001279:Atracurium / Q000008:administration & dosage / Q000009:adverse effects; D003362:Cost-Benefit Analysis; D003422:Critical Care / Q000191:economics / Q000592:standards; D004358:Drug Therapy; D004573:Electrolytes / Q000032:analysis; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic / Q000191:economics / Q000592:standards*; D009119:Muscle Contraction / Q000187:drug effects; D018482:Muscle, Skeletal / Q000187:drug effects / Q000294:innervation; D009468:Neuromuscular Diseases / Q000139:chemically induced / Q000517:prevention & control; D009469:Neuromuscular Junction / Q000187:drug effects*; D003473:Neuromuscular Nondepolarizing Agents / Q000008:administration & dosage* / Q000009:adverse effects; D010243:Paralysis / Q000139:chemically induced / Q000517:prevention & control; D011446:Prospective Studies; D012046:Rehabilitation / Q000191:economics; D012121:Respiration, Artificial / Q000191:economics; D012189:Retrospective Studies; D012307:Risk Factors; D013933:Thumb; D014673:Vecuronium Bromide / Q000008:administration & dosage / Q000009:adverse effects
D004573:Electrolytes; D003473:Neuromuscular Nondepolarizing Agents; D001279:Atracurium; D014673:Vecuronium Bromide